Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
RGRX's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.65 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Regenerx Biopharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2023 was $0.013. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.07 for the trailing ten years ended in Mar. 2023.
Shiller PE for Stocks: The True Measure of Stock Valuation
Regenerx Biopharmaceuticals (OTCPK:RGRX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Related Terms
Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Chart
RGRX vs MYMX, RGMP, NBRVF: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Regenerx Biopharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.01 mean?
Regenerx Biopharmaceuticals (RGRX) has a Cyclically Adjusted PS Ratio of 0.01 as of Jul. 23, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Cyclically Adjusted PS Ratio too high?
Regenerx Biopharmaceuticals' current Cyclically Adjusted PS Ratio is 0.01. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.65. Regenerx Biopharmaceuticals' value of 0.01 is 99.8% below this industry median.
How does Regenerx Biopharmaceuticals' Cyclically Adjusted PS Ratio compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Cyclically Adjusted PS Ratio of 0.01 can be compared against companies in the Biotechnology industry. The industry median Cyclically Adjusted PS Ratio is 5.65. Regenerx Biopharmaceuticals' value of 0.01 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.65, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerx Biopharmaceuticals's current Cyclically Adjusted PS Ratio of 0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Regenerx Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerx Biopharmaceuticals's current Cyclically Adjusted PS Ratio is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Cyclically Adjusted PS Ratio of 0.01. The current Cyclically Adjusted PS Ratio is 0.01 and 99.8% below the Biotechnology industry median of 5.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Cyclically Adjusted PS Ratio is 0.01 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGRX has been successfully added to your 
